? Medtechs eye key role of ASCs in return of elective care | Bain & Company

Bain uses cookies to improve functionality and performance of this site. More information can be found in our Privacy Policy. By continuing to browse this site, you consent to the use of cookies.

Medtech Dive

Medtechs eye key role of ASCs in return of elective care王者荣耀赌外围,王者荣耀赛事赌博?,英雄联盟比赛竞猜

Medtechs eye key role of ASCs in return of elective care王者荣耀赌外围,王者荣耀赛事赌博?,英雄联盟比赛竞猜

The flight of joint replacements and other lucrative procedures from acute care hospitals to ambulatory surgery centers was happening before the COVID-19 pandemic, but the crisis may prove to accelerate the trend

  • May 26, 2020
  • min read

Medtech Dive

Medtechs eye key role of ASCs in return of elective care

The flight of joint replacements and other lucrative procedures from acute care hospitals to ambulatory surgery centers was happening before the COVID-19 pandemic, but the crisis may prove to accelerate the trend.

“That shift was underway, but not very quickly: things never are in healthcare,” said Tim van Biesen, head of Bain & Company’s global healthcare practice.

Some 5,700 ASCs in the U.S. carried out 23 million procedures in 2018, according to data cited by Bain last fall. The year prior, ASCs reportedly carried out more than half of all outpatient surgeries, versus having 32% share 15 years ago.

See more on Medtech Dive